Scancell Share Discussion Threads

[wanderer1210_0] 09/7/2021 14:30

Diagnosed him years ago. Narcissistic personality disorder - one of several types of personality disorders - is a mental condition in which people have an inflated sense of their own importance, a deep need for excessive attention and admiration, troubled relationships, and a lack of empathy for others. But behind this mask of extreme confidence lies a fragile self-esteem that's vulnerable to the slightest criticism.Take a break, your obsession is unhealthy.

[panama7] 09/7/2021 14:29

So Big Pharma & Big Government want everybody to take the shot but don't want any liability. So Big Pharma and certain individuals will make billions but anyone injured it's just tough luck. hxxps://childrenshealthdefense.org/defender/hundreds-injured-covid-vaccines-gofundme-expenses/?utm_source=salsa&eType=EmailBlastContent&eId=04efec71-8531-42cd-8bae-818ea0502083

[ivyspivey] 09/7/2021 13:21

Inanaco.
I am very happy with my investment there and we have out fair bet.
They have no need to ever raise again(CEO promise) and if both get to £1 we will get seven figure returns so sure we will both be very happy
Can we just leave the discussion on here to SCLP as others will be bored discussing other stocks.

[inanaco] 09/7/2021 12:55

25,000 shares ... cant see any further buys .... and then you went Antivax ...




wanderer1210_0 - 12 Mar 2018 - 14:54:32 - 14546 of 41854 Using immunology to fight cancer. - SCLP
Lordy me, seems I’m a very popular topic on the board today.
No margin to trade it now, floating between 17.5p and 18.5p, I’ve enough skin in this atm with 25k shares that cost me nowt, with a cash raise on the horizon I’ve deduced that putting capital in the stock is not a option just now, my initial investment was £12.5k that gave me my money back £1k profit and 25k free shares.
So no I didn’t make thousands and also will not be buying back in with the £12.5k, there are better trading options out there just now.
ATB



wanderer1210_0 - 18 Oct 2019 - 17:46:37 - 25812 of 41854 Using immunology to fight cancer. - SCLP
Greetings
The fact of the matter is this as been a poor investment, if it remains one we will see, but for the investors who bought in the 60's it's going to be a uphill struggle from here.
The science is not stacking up after years of hype from you know who and the BOD's.
From here if Scancell continue are 5-6 more years of dilution and a wavering share price before any deal can be struck if any at all.
Good luck if your still in here, you're going to need it.

[inanaco] 09/7/2021 12:22

Orph

Ivy but that involves high capital cost ... and a possible raise to cover that expansion I appreciate that sits on the Asset side of the accounts and can be written down over years .. however that assumes you can maintain occupancy

[inanaco] 09/7/2021 12:19

Ivy if they do, you are not going to buy at 22p

holding a Core for this very reason

Tosh
ONW
Loggie
Bermuda
Inanaco
Gazza
Ivy ?
Wanderer
P7
Tf
Mia
EE
wildforce
stan
Kat
C7
C11

this list goes on and on ........................................................

except for ....... Lozan

however Redmile think we will ..... and so does Vulpes

Ivyspivey Premium Member

Posts: 12,073

Price: 22.25

No Opinion

RE: Turning cold tumours hot09 Jul 2021 11:49
Hi Miavoce,
As you have pointed out use of a single word can change the tone of a post.
My use of the word “ independent “ is mainly used in connection with the SCIB 1 compelling data which is the one in which the biggest validation has probably been seen.
It is independent data in sense that it is in a regulated trial but it is has not for whatever reason been “ validated” by the people who will value and buy these assets ie big pharma and that is my distinction.
Perhaps I should use another word but I mean validated by someone with the ability to value and monetise it to a suitable level forcSCLP to do a deal

[ivyspivey] 09/7/2021 12:10

Hi Inanaco,
They have had a big seller( historical CEO) to drag share price down but stabilising now on today’s news.They can increase capacity as they did when a client wanted a HC study so badly they actually paid for a hotel conversion into a quarantine facility.
They could also partner with SGS who are just building a big new facility in Belgium that needs filling.
Means they can charge higher prices plus with a CRO with big fixed overheads it is all about maximising capacity which they are doing.

[inanaco] 09/7/2021 12:01

Ivy
I see Orph is now running at capacity indeed booked into next year to ...
as they have said they are now profitable .. once declared that will give you a pretty good indication going forward ... the share price now 27

[inanaco] 09/7/2021 11:25

It would be very interesting to see a comment from Ivy directed at Lozan

Golden chance pal ... after his latest outburst

[inanaco] 09/7/2021 11:21

Ivy the point i am trying to make ........

you "elevate" not validated ... like its a On Off Switch ...

without any positives of whats known .... and what scancell has done in its research


like Lindy said ... in 30 years i have never seen anything like it .. these t cells are truly amazing

[inanaco] 09/7/2021 11:12

Oh and just remember MD Anderson have mapped that environment and concluded the targets do exist !!

[inanaco] 09/7/2021 11:05

that is what the trials are for ....

but it does not stop ... even if efficacy is low

if scancell has functional T cells identified in trial they will also see what happens in a Soild cancers regarding the environment

the industry is developing extremely quickly to modify that environment

what the industry does not have is Targets .... they are so rare

Moditope has a huge repertoire of targets

we are at the start ... its not going to end any time soon

[ivyspivey] 09/7/2021 10:59

OK but it is the level of efficacy which will largely validate the data

[ivyspivey] 09/7/2021 10:58

Inanaco regarding Moditope once we have sufficient human results then we can talk about true validation or not

[ivyspivey] 09/7/2021 10:57

PS I have corrected by mistake posted by Miavoce about putting “ invalidated” when I meant “ unvalidated “
Apologies

[inanaco] 09/7/2021 10:56

so if you are going to present Moditope as unvalidated

you have to be very specific in that we do have natural T cells that recognise the modi1 peptides ... that is a fact

which means they will activate

Fact

missing is "Efficacy" we don't know yet

[inanaco] 09/7/2021 10:48

Lindy has got Human T cells activated by Moditope .......

SO we will see ""activity"" .......... Validated ...

with BioNtech lindy is looking for the "High Avidity" before cloning ...

however scancell has yet to find one of sufficient calibre to give confidence to clone

but that is not to say they won't

It is known that stimulation of low-avidity T cells requires co-ligation of CD8, however this is often dispensable in high-avidity cells [67,68]. T cells are very susceptible to CD8 co-ligation at the initiation of an antiviral response, while 8 days later following avidity maturation, this ligation is expendable [65]. Furthermore, no changes in TCR affinity or expression of adhesion or co-stimulatory molecules were found, which could explain the enhanced antigen responsiveness. Instead, they identified a marked increase in Lck expression. This kinase is associated with the cytoplasmic domain of the CD4 and CD8 coreceptors, mediating ITAM phosphorylation on accessory chains of the TCR complex. Additionally, changes in the TCR-surrounding plasma membrane were found to aid increased avidity after T-cell activation [69]. It appears that T cells will gradually reorganize and cholesterol-enrich their membrane lipid rafts upon activation, in which the TCR and many co-stimulatory molecules are embedded. This reorganization enhances TCR cross-linking and the formation of the SMAC, allowing T cells to bind multimeric MHC complexes with improved efficiency, enhancing intra-cellular signaling. This allows more efficient recognition of low-density peptide-MHC complexes.

-----------------------------------------------------------------------------------
or in other words once in Battle the T cells gain avidity over time

Not good against a Virus because 8 days .... allows the virus to get a foothold
so induce High Avidity with Scovs solves that delay

however 8 days with moditope "working" should give us abundant high avidity to clone

[ivyspivey] 09/7/2021 10:39

Trinity Dekta validated but not in human truals

[ivyspivey] 09/7/2021 10:38

Morning Inanaco,
I am doing nothing of the sort.
My post was in direct response and agreement with Trebor post.
I will restate as it is a very simple concept to understand.
SCLP have been saying since 2015 that they need to get into trials and generate data so that big pharma can evaluate and validate this data in line with SCLPs confidence in the science.
So far they have not progressed their platforms into trials to generate this data.
So Modi and Covidity into humans and Immunobody either as monotherapy or in Combo with CIs beyond the SCIB 1 trial ongoing in 2015.

What in my post is not true.

I really thought that Trebors post “may generate we are minted response”.
Hope you see the funny side lol

[emptyend] 09/7/2021 10:12

I heard from friends today that NZ is struggling with its Covid19 vaccine rollout. I also read on Bloomberg that the Indian economy is in dire straits, erasing decades of progress .So the thought occurred to me : how long before such relatively wealthy countries start seeking more control over vaccine supplies by taking positions in the vaccine value-chain? Clearly their ability to influence anything is minimal if they take a piece of Pfizer, AZ etc.......but they could (ignoring Redmile for a moment) take control of a company the size of Scancell?? And if they did, they could arrange partnerships that included supply conditions, very much as the UK has done (and the EU thought it had done).Will substantial (but economically second-tier) sovereign nations stay on the sidelines waiting for whatever the top-tier nations choose to offer them? Or will their domestic politics drive demands that their governments become more pro-active? Will Thailand, for example, continue to be comfortable relying on China? What about Japan.....a country that has some massive pharma businesses but no indigenous current front-line vaccine (and one which is about to suffer an unprecedented national loss of face by hosting the first people-less Olympics)? Surely that cannot continue?